Altimmune rises on plans to test obesity drug for alcohol use disorder, other conditions

Altimmune

14/03/2025 12:29

** Shares of drug developer Altimmune ALT.O rise 4.62% to $5.44 premarket

** Co said on Thursday it plans to test its experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease

** Expects to begin a mid-stage study for alcohol use disorder in Q2, and for alcohol-associated liver disease in Q3

** brokerage Evercore ISI says this adds another leg to the pemvidutide story and one that ALT can take the lead in

** Stock down ~52% in the last 12 months

 (Reporting by Sriparna Roy in Bengaluru)

 ((Sriparna.Roy@thomsonreuters.com;))